<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390672</url>
  </required_header>
  <id_info>
    <org_study_id>NUIG-2020-002</org_study_id>
    <nct_id>NCT04390672</nct_id>
  </id_info>
  <brief_title>Multivessel TALENT</brief_title>
  <official_title>A Randomized Controlled Trial to Compare the Safety and Efficacy of siroliMUs-eLuTIng Biodegradable Polymer ulTrA-thin Stent (SUPRAFLEX Cruz) and Everolimus-eLuting Biodegradable Polymer Stent (SYNERGY) in treatmENT for Three-vessel Coronary Artery Disease: Multivessel TALENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Ireland, Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Ireland, Galway, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multivessel TALENT is a prospective, randomized, multi-center study comparing clinical&#xD;
      outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three&#xD;
      vessel disease undergoing percutaneous coronary intervention (PCI). Patients will be treated&#xD;
      according to &quot;state of art PCI&quot;; not only treatment strategies based on the latest ESC&#xD;
      guideline, such as SYNTAX Score II recommendation, Heart Team discussion, post-procedure&#xD;
      intravascular imaging optimization, cholesterol reduction by statin or PCSK-9 inhibitor, but&#xD;
      also exploratory treatment strategies based on the latest evidence, such as physiological&#xD;
      assessment using quantitative flow ratio and prasugrel monotherapy following 1-month dual&#xD;
      antiplatelet therapy after PCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a composite of all cause death, any stroke, any myocardial infarction (MI), and any (repeat) revascularisation</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>a non-inferiority comparison of Patient-oriented Composite Endpoint (POCE) of the SUPRAFLEX Cruz cohort to the SYNERGY cohort at 12 months post-procedure. POCE is a composite clinical endpoint of:&#xD;
All cause death;&#xD;
Any stroke, Modified Rankin Scale (MRS ≥1);&#xD;
Any myocardial infarction (MI);&#xD;
Any (repeat) revascularisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of vessels with a composite of vessel-related cardiovascular death, vessel-related MI, or CPI-TVR (clinically and physiologically-indicated-Target vessel revascularisation)</measure>
    <time_frame>24 months post-procedure</time_frame>
    <description>a superiority comparison in the as treated population (per vessel level) of the vessel-oriented composite endpoints (VOCE).&#xD;
VOCE is a composite clinical endpoint of:&#xD;
Vessel-related cardiovascular death;&#xD;
Vessel-related MI;&#xD;
CPI-TVR (clinically and physiologically-indicated-Target vessel revascularisation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a composite of all cause death, any stroke, any myocardial infarction (MI), and any (repeat) revascularisation</measure>
    <time_frame>24 months post-procedure</time_frame>
    <description>a comparison of Patient-oriented Composite Endpoint (POCE) of the SUPRAFLEX Cruz cohort to the SYNERGY cohort at 24 months post-procedure. POCE is a composite clinical endpoint of:&#xD;
All cause death;&#xD;
Any stroke, Modified Rankin Scale (MRS ≥1);&#xD;
Any myocardial infarction (MI);&#xD;
Any (repeat) revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with all cause death</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any stroke</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with any stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any myocardial infarction</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with any myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any (repeat) revascularisation</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of number of participants with any (repeat) revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vessels with vessel-related cardiovascular death</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of vessels with vessel-related cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vessels with vessel-related MI</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of vessels with vessel-related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vessels with CPI-TVR (clinically and physiologically-indicated-Target vessel revascularisation)</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of vessels with CPI-TVR (clinically and physiologically-indicated-Target vessel revascularisation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a composite of cardiovascular death, target vessel MI and clinically-indicated target lesion revascularization</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with TLF / DOCE defined as cardiovascular death, target vessel MI and clinically-indicated target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a composite of cardiovascular death, target vessel MI and clinically-indicated target vessel revascularisation</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with TVF defined as cardiovascular death, target vessel MI and clinically-indicated target vessel revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with cardiovascular death</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with target vessel MI</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with target vessel MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically-indicated target lesion revascularisation</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with clinically-indicated target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Definite/Probable Stent thrombosis</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
    <description>a comparison of numbers of participants with Definite/Probable Stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with device success</measure>
    <time_frame>7days post-procedure</time_frame>
    <description>a comparison of numbers of participants with device success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with procedure success</measure>
    <time_frame>7days post-procedure</time_frame>
    <description>a comparison of numbers of participants with procedure success (Device success + free from POCE at discharge)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1550</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Disease</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>SUPRAFLEX Cruz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYNERGY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SUPRAFLEX Cruz</intervention_name>
    <description>Percutaneous Coronary Intervention for multivessel disease</description>
    <arm_group_label>SUPRAFLEX Cruz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY</intervention_name>
    <description>Percutaneous Coronary Intervention for multivessel disease</description>
    <arm_group_label>SYNERGY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients' ≥18 years.&#xD;
&#xD;
          2. At least 1 stenosis (angiographic, visually determined de novo lesions with ≥50% DS)&#xD;
             in all 3 major epicardial territories (LAD and/or side branch, LCX and/or side branch,&#xD;
             RCA and/or side branch) supplying viable myocardium without left main involvement.&#xD;
&#xD;
          3. The vessel should have a reference vessel diameter ranging from ≥2.25 mm to ≤4.50 mm&#xD;
             (no limitation on the number of treated lesions, vessels, or lesion length).&#xD;
&#xD;
          4. Patients with chronic coronary syndrome or stabilized acute coronary syndromes.&#xD;
&#xD;
          5. All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX Score&#xD;
             II, provided that the SYNTAX Score II recommends equipoise risk (PCI or CABG) or PCI&#xD;
             only.&#xD;
&#xD;
          6. Patient has been informed of the nature of the study and agrees to its provisions and&#xD;
             has provided written informed consent as approved by the Ethical Committee and is&#xD;
             willing to comply with all protocol-required evaluations.&#xD;
&#xD;
          7. Agree with conditional longer follow up from 2 to 5 years with one phone contact&#xD;
             yearly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under the age of 18.&#xD;
&#xD;
          2. Unable to give informed consent.&#xD;
&#xD;
          3. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed&#xD;
             within 7 days prior to the index procedure in women of child-bearing potential&#xD;
             according to local practice).&#xD;
&#xD;
          4. Known contraindication to medications such as Aspirin, Heparin, Bivalirudin, Prasugrel&#xD;
             and Ticagrelor.&#xD;
&#xD;
          5. Prior PCI or prior CABG.&#xD;
&#xD;
          6. Ongoing ST-elevation myocardial infarction (STEMI).&#xD;
&#xD;
          7. Cardiogenic shock is also an exclusion criteria.&#xD;
&#xD;
          8. Concurrent medical condition with a life expectancy of less than 2 years.&#xD;
&#xD;
          9. Currently participating in another trial and not yet at its primary endpoint.&#xD;
&#xD;
         10. Patient with both ostial LAD and ostial LCX stenosis, or left main stenosis.&#xD;
&#xD;
         11. Previous intracranial haemorrhage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick W. Serruys, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National University of Ireland, Galway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Wijns, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National University of Ireland, Galway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshinobu Onuma, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National University of Ireland, Galway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helge Moellmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Johannes Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manel Sabate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azfar Zaman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freeman Hospital and Newcastle University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hironori Hara, MD</last_name>
    <phone>+31626459601</phone>
    <email>hironorihara1022@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NUIG</name>
      <address>
        <city>Galway</city>
        <zip>H91TK33</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Sharif</last_name>
      <phone>091524411</phone>
      <email>faisal.sharif@nuigalway.ie</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Ireland, Galway, Ireland</investigator_affiliation>
    <investigator_full_name>Patrick Serruys</investigator_full_name>
    <investigator_title>Established Professor of Interventional Medicine and Innovation, National University of Ireland, Galway (NUIG), Galway, Ireland</investigator_title>
  </responsible_party>
  <keyword>multi-vessel coronary artery disease</keyword>
  <keyword>revascularization</keyword>
  <keyword>quantitative flow ratio</keyword>
  <keyword>fractional flow reserve</keyword>
  <keyword>instant wave-free ratio</keyword>
  <keyword>SYNTAX score</keyword>
  <keyword>prasugrel monotherapy</keyword>
  <keyword>ultra-thin strut sirolimus-eluting coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

